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Abstract 
 
Problem: Postpartum hemorrhage, heavy bleeding that occurs after birth, is the leading cause of 
maternal morbidity and mortality worldwide, affecting up to 5% of all births. Rates of 
postpartum hemorrhage continue to rise in the United States, despite acknowledgement of this 
complication and its’ impact on maternal health. Emphasis has been placed on early 
identification of risk factors for hemorrhage and creation of protocols to improve 
interprofessional efficiency when managing a postpartum hemorrhage. Management of this 
complication requires interprofessional collaboration amongst healthcare professionals, including 
nursing staff, Certified Nurse-Midwives, obstetrician/gynecologists, anesthesia providers, and 
others.  
Project Aim: This Doctor of Nursing Practice quality improvement project aimed to: (1) develop 
an evidence-based protocol for PPH, which will: (a) increase early identification of postpartum 
hemorrhage after birth; and (b) improve interprofessional collaboration during an active PPH 
emergency. 
Project Method: This evidence-based protocol was developed based on the Iowa Model of 
Evidence-Based Practice to Promote Quality of Care and will identified women at greater risk 
for hemorrhage and outline an interprofessional postpartum hemorrhage protocol. A team of 
healthcare professionals, representing different healthcare professions that care for patients 
during postpartum hemorrhage, evaluated the protocol utilizing the AGREE II evaluation tool. 
Project Results: Surveys were distributed using RedCap with a sample of 26 participants: 22 
(84.6%) registered nurses, three (11.5%) Certified Nurse Midwives and one (3.8%) obstetrician.    
Responses communicated a desire for a PPH protocol within this local community hospital. 
Survey responses and comments were used to revise the PPH protocol. 
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Interprofessional Review of a Postpartum Hemorrhage Protocol 
 
 Postpartum hemorrhage (PPH) is the cause of death for approximately 140,000 women 
every year, and 45% of maternal morbidity is associated with PPH (ModernMedicine Network, 
2017). Maternal morbidity is defined as negative effects due to pregnancy or childbirth. For this 
project, maternal morbidity refers to negative physical impacts due to childbirth. Maternal 
mortality is maternal death due to pregnancy and childbirth. The United States ranks 47th in the 
world for maternal mortality. The rate of PPH has increased and continues to rise. It occurs at a 
rate between 1-5% of all births (ModernMedicine Network, 2017), which translates to, 125,000 
women a year who are affected by PPH, and a 183% increase in the number of women receiving 
blood products at birth (Association of Women's Health, Obstetric and Neonatal Nurses 
[AWHONN], 2017).  
The average blood loss for a vaginal delivery is 500 mL and 1000 mL for a cesarean 
delivery (Best Practices, 2017). Postpartum hemorrhage was previously defined as a vaginal 
delivery with 500 mL or greater blood loss and Cesarean delivery with 1000 mL or greater blood 
loss.  PPH was redefined in 2017 by the American College of Obstetricians and Gynecologists 
(ACOG), as a total blood loss of 1000 mL or greater, no matter the route of delivery, or 
significant blood loss post-delivery with symptomatic hypovolemia. Hemorrhage after birth is 
classified as either primary or secondary.  
Primary PPH is defined as a cumulative blood loss of 1000 mL or more within the first 
24 hours of delivery regardless of route of delivery.  It is also defined as significant blood loss 
with symptoms of hypovolemia, including tachycardia and hypotension, that occurs within the 
first 24 hours of delivery. All women with a total blood loss of 500 to 1000 mL postpartum 
should be monitored closely and may require PPH intervention to prevent further morbidity or 
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mortality (Best Practices, 2017).  A blood loss greater than 500 mL for a vaginal delivery, while 
not diagnostic of a PPH, is not considered normal and deserves additional surveillance.  
 Secondary PPH is defined as excessive vaginal or uterine bleeding that occurs between 
24 hours post-delivery up to 12 weeks postpartum. The risk of secondary PPH peaks during the 
first two weeks postpartum.  
Statement of Problem 
 
 The rate of PPH within the United States continues to grow. As PPH rates increase, there 
is a greater importance regarding early identification of risk factors for hemorrhage and 
improving interprofessional efficiency during management of the hemorrhage (California 
Maternal Quality Care Collaboration [CMQCC], 2015).  A PPH protocol aims to identify PPH 
earlier through accurate blood loss calculation and identification of women at high risk for PPH. 
The protocol also improves timely implementation of hemorrhage interventions, including: (a) 
medication administration; (b) second IV starts; (c) administration of blood products; (d) uterine 
tamponade techniques; and (e) surgical intervention, when appropriate.  The protocol not only 
identifies tasks to be completed, but also identifies which team members should be notified and 
what each individual should be doing to manage the PPH. Early identification is key to 
appropriately managing PPH as most women do not become symptomatic of PPH until a 
significant amount of blood has been lost (ACOG, 2017). PPH symptoms typically occur when 
25%, or approximately 1500 mL of blood, has been lost (ACOG, 2017). This amount of blood 
loss leads to vital sign changes including hypotension and tachycardia. When a patient is 
symptomatic of blood loss there is less time to manage the PPH with minimal interventions 
alone, such as medication or blood administration.   
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 The first step in early identification of PPH is to identify women at greater risk for PPH 
on admission, before delivery has happened (ACOG, 2017). PPH admission tools are shown to 
identify 60-85% of patients who will have a PPH (ACOG, 2017). PPH can occur in low-risk 
women, but is more likely to occur in women with higher risks of PPH (ACOG, 2017). PPH 
categories include low-risk, medium-risk and high-risk women (ACOG, 2017). Women at low 
risk for PPH have the following characteristics: (a) singleton gestation; (b) less than 4 previous 
deliveries; (c) unscarred uterus; and (d) no history of a PPH with previous deliveries.  Medium-
risk women are categorized as those having at least one of the following characteristics: (a) prior 
cesarean section or uterine surgery; (b) more than 4 previous deliveries; (c) multiple gestation; 
(d) large uterine fibroids; (e) chorioamnionitis; (f) magnesium sulfate use; and (g) prolonged use 
of oxytocin. Women at high risk for PPH include those with: (a) placenta previa, accreta, increta 
and percreta; (b) hematocrit less than 30; (c) bleeding at admission; (d) known bleeding 
disorders; (e) history of postpartum hemorrhage; and (f) abnormal vital signs, such as 
hypotension and tachycardia (ACOG, 2017).  
 There are four causes of PPH, also referred to as “the 4 Ts”: tone; trauma; tissue; and 
thrombin. As acknowledged previously, uterine tone is responsible for approximately 70 to 80% 
of all PPH incidences. The other three etiologies are responsible for the remaining 20-30% of 
PPH incidence.  Management of uterine atony includes uterotonics, bimanual compression and 
uterine massage. Active management of the third stage of labor, aimed at addressing uterine 
tone, is recognized as the number one preventative treatment for PPH. Active management of the 
third stage of labor includes 10 units of oxytocin administration, intravenous or intramuscular, 
after the delivery of the anterior fetal shoulder or administration after placental delivery. Both 
administration routes for oxytocin are appropriate and neither is proven to be more effective than 
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another. The other components to active management of the third stage of labor are to give 
continual cord traction on the placenta and uterine massage (ACOG, 2017). 
 “Trauma” includes any laceration caused by birth, such as lacerations to perineal tissue or 
cervix, hematomas, and uterine rupture.  “Tissue” involves any foreign tissue retained after 
delivery, which may include retained membranes, retained placentas in their entirety, and 
retained placental fragments.  Retained tissue can be managed using manual removal, curettage, 
and/or ultrasound visualization for identification. “Thrombin” refers to identifying any bleeding 
disorders that may lead to PPH. Bleeding disorders can be mitigated by utilizing replacement of 
clotting factors, fibrinogen, and other factor replacement sources (ACOG, 2017).  
 PPH is often misdiagnosed due to implementation of visual estimation of blood loss, 
leading to an overestimation or underestimation of blood loss (Dildy, 2018). The most accurate 
way to estimate blood loss is to weigh all pads, peri pads, and cumulative blood loss. Literature 
shows that visual estimation of blood loss can prolong active management of PPH due to its 
inaccuracy. Weighing blood lost post delivery can lead to earlier PPH intervention and mitigate 
bleeding prior to the need for more invasive medical intervention, such as operative management 
of PPH, hysterectomy, and blood product administration. Systematic blood loss estimation is 
more effective when determining blood loss (Dildy, 2018).  
 Pregnant women have three times the amount of blood than the non-pregnant individual. 
This extra blood volume works to not only supply the fetus and placenta with oxygenated blood, 
but to also prepare the maternal body for blood loss postpartum (Posner e al., 2013). It is normal 
to lose some blood during birth and in the postpartum period. All women lose an average of 
approximately 500 mL of blood during a vaginal birth.  If 500 mL or greater of blood loss is 
noted, it is important to identify the source of bleeding and recognize this as abnormal. Women 
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who have normal lab work prior to labor onset, including hematocrit and hemoglobin, can easily 
withstand this amount of blood loss with minimal to no symptoms (ACOG, 2017). When women 
are anemic or have lab work not indicative of blood loss tolerance, there is not as much reserve 
when it comes to blood loss. Any time a woman, no matter the amount of blood loss, is 
symptomatic of hypovolemia it is important to identify and stop the source of bleeding 
(California Maternal Quality Care Collaboration [CMQCC], 2015). PPH may not be a large 
amount of blood at one time but a continuous trickle of bleeding.  It is important for nursing staff 
to identify continuous bleeding in the recovery period, not solely large gushes of bleeding and 
focus more on cumulative blood loss (Posner et al., 2013).  
 PPH protocol and checklists have been shown to increase interprofessional collaboration 
and early management during an active PPH. Interprofessional collaboration is defined as any 
hospital personnel caring for postpartum hemorrhages including: obstetricians, midwives, 
anesthesiologists, nursing staff, obstetrical technicians, blood blank staff, lab staff, pharmacy 
staff and other surgical staff (Dildy, 2018).  All members of the team should be well educated 
and informed on postpartum hemorrhage and its unpredictability. Use of an organized and 
collaborative approach through PPH checklists, carts, protocols and early identification tools can 
lead to decreased incidents of PPH, maternal morbidity, invasive procedures and admission to 
intensive care units (ACOG, 2017).  In turn, consistent use of a PPH protocol for any occurrence 
of primary PPH, works to improve patient outcomes (ModernMedicine Network, 2017). 
Project Aims  
 
 This Doctor of Nursing Practice quality improvement project aimed to: (1) develop an 
evidence-based protocol for PPH, which will: (a) increase early identification of postpartum 
hemorrhages after birth; and (b) improve interprofessional collaboration during an active PPH 
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emergency. 
Theoretical Framework 
 
 The theoretical framework utilized for design of this project was the Iowa Model of 
Evidence-Based Practice to Promote Quality of Care (Appendix A). This model focuses on seven 
steps to implement change within the clinical setting. The seven steps of the Iowa Model include: 
(1) identify the problem; (2) determine the priority level of the problem at the orginizational 
level; (3) form a team to address the problem; (4) collect and synthesize the research evidence 
regarding the problem; (5) pilot the practice change; (6) evaluate the implementation and 
continuation in practice; and (7) dissemnate the results (Melnyk & Fineout-Overholt, 2011). The 
focus of this project was the first four steps of this model, because no change was piloted. 
Development of a PPH protocol and interprofessional review occurred. This theoretical 
framework is applicable regarding the review of an interprofessional PPH protocol because it is a 
multidiscplinary healthcare team approach to identifying the problem and implementing change 
at the organizational level. 
 This project has the potential to impact maternal mortality and morbidity rates at a local 
hospital and its outlying communities. The impact also goes beyond health and well being; if 
change is succesful in reducing PPH rates and increasing active interprofessional collaboration, a  
potential decrease in healthcare costs for PPH managment and treatment could occur within the 
organization, at the community level, and at the state level. The Iowa Model is most appropriate 
because the topic of PPH managment and interprofessional collarboration requires a team-based 
approach for how to improve these rates and implement new practices in the hosptial setting. 
Methods 
Design 
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 An evidence-based practice protocol was developed for this quality improvement project 
utilizing the most current information on PPH identification and managment, including use of 
recommendations from reputable sources. An interprofessional team was then asked to evaluate 
the protocol and revisions were made prior to dissemination.  
Setting. The setting for this quality improvement project was a local Midwestern, 
community-based hospital that serves a population of 64,000 and many outlying rural 
communities. The hospital has a maternity ward with 17 labor and postpartum beds. The 
providers that care for patients in the maternity ward is composed of three Certified Nurse-
Midwives and nine Obstetricians.  The unit has approximately 1800 births a year. 
Procedure 
Development of Protocol. This evidence-based PPH protocol was developed after an 
extensive review of the literature, including standardized, widely-distributed professional 
guidelines. A literature matrix (See Appendix B) was developed to compare recommendations 
and best practices.  The protocol was modeled after the California Maternal Quality Care 
Collaboration (CMQCC) OB Hemorrhage Toolkit (2015) and ACOG Postpartum Hemorrhage 
Bulletin (2017). 
 Evaluation of Protocol. The protocol and evlauation survey was distributed to a diverse 
group of healthcare professionals who take part in PPH managment at the community hospital. 
After reading through the protocol, individuals were asked to assess the protocol utilizing the 
evaluation tool (See Appendix C). Providers were then asked to consider the feasibility of the 
protocol and appropriateness for this particular community-based hospital setting.  
 The evaluation tool utilized in this project was the AGREE II evaluation tool from the 
Appraisal of Guidelines for Research and Evaluation (AGREE) project (Brouwers et al, 2010).  
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The AGREE evaluation tool is a standardized tool to systematically review quality improvement 
guidelines and protocols. There are 23 items assessed using a Likert-like scale from 1 to 7, 
ranging from strongly disagree (1) to strongly agree (7). This tool establishes a quantifiable 
approach to analyzing quality improvement projects.  This tool has been cited 100 times and is 
used internationally (Cruz, Fahim, & Moore, 2015).  
  Once the protocol was developed, the protocol was issued to clinicians and survey 
responses were collected. Suvey repsonses were be collected using REDCap, a secure web 
application for building and managing online surveys (Harris, 2009).  This system worked to 
collect data and oragnize it within the same system and keep anyonmity for participants.  
Analysis. Data was collected using an evaluation tool based on the AGREE II (See 
Appendix C). The evaluation tool identified any recommendations, suggestions, or changes to be 
made to the protocol. The surveys were later reviewed and the data summarized with descriptive 
statistics, including range, mean, and standard deviation.  
 Human Subject Protection. This project was submitted to the Institutional Review 
Board (IRB) for designation as a quality improvement project. The IRB approved the project to 
ensure participant safety and ethical considerations.. Prior to the start of the project, designation 
as a quality improvement project was obtained (Appendix D).  
Results 
 
 The PPH protocol survey (See Appendix E) was distributed via email and social media 
links to the registered nurses, certified nurse-midwives and obstetricians of a local community 
hospital. The survey invitation was sent to 50 labor and delivery registered nurses and thirteen 
obstetrical providers. The response rate was 41.3% (N=26) out the 63 asked to complete the 
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survey. The sample size was categorized into three categories: 22 (84.6%) registered nurses, 
three (11.5%) certified nurse-midwives and one  (3.8%) obstetrician.   
 The survey questions of the AGREE II evaluation tool were broken down into 7 domains. 
These domains include: Domain 1: Scope and Practice; Domain 2: Stakeholder Involvement; 
Domain 3: Rigor of Development; Domain 4: Clarity of Presentation; Domain 5: Applicability; 
Domain 6: Editorial Independence and; Domain 7: Recommendations.  The answers from 
participants for the first 6 domains utilized a Likert-like scale of agreement from 1 to 7, with 1 
being “strongly disagree” and 7 “strongly agree.”   
 The first domain assessed the scope and practice of the PPH protocol with three 
statements included with in this domain. The first statement assessed, “The overall objectives of 
the protocol are specifically described”. Approximately 96.1% of participants had some level of 
agreeability (“partially agree” to “strongly agree”) to the specificity of the overall objectives of 
the protocol. The second statement of domain 1 assessed, “The health questions covered by the 
protocol are specifically described”. Again, approximately 91% reported some level of 
agreement with the statement. The final statement of this domain assessed, “The population 
(patients, public, etc.) to whom the guideline is meant to apply is specifically described”.  
Participant responses to this statement revealed 95% agreement. 
 The second domain utilized to assess the PPH protocol identified stakeholder 
involvement.  The first assessment regarding stakeholder involvement was, “The protocol 
includes individuals from all relevant professional groups”.  Participant responses to this 
assessment included: partially disagree (1, 3.8%); agree (8, 30.8%) and strongly agree (17, 
65.4%).  There were no comments that included other professional groups that would be 
pertinent to assess, despite the results from participants indicating need for other relevant 
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professional groups. 
 The second assessment of this domain identified, “The views and preferences of the 
target population (patients, public, etc.) have been sought”. Responses to this assessment 
included: partially disagree (1, 3.8%); neutral (2, 7.7%); agree (7, 26.9%); and strongly agree 
(16, 61.5%).  The final assessment in this domain included, “The target users of the protocol are 
clearly defined”. Participants responses ranged from 5, partially agree, to 7, strongly agree. No 
comments from participants were included regarding this assessment. 
 The third domain assessed the rigor of development of the PPH protocol, including eight 
assessment statements to this domain. This domain was the longest in regards to number of 
participant assessments. One of the eight assessments included “The health benefits, side effects, 
and risks have been considered in formulating the recommendations”.  Participants responses 
ranged from 5, partially agree, to 7, strongly agree. Another assessment of the third domain 
included, “There is an explicit link between the recommendations and the supporting evidence”. 
There were differing levels of agreement amongst participants with, participants responses 
ranged from 5, partially agree, to 7, strongly agree.  The final assessment highlighted from this 
domain, “A procedure for updating the protocol is provided”.  This had the greatest range of 
responses from participants on the entire survey. The bar graph in Figure 1 specifically 
demonstrates the participant number and responses with: disagree (1, 3.8%); neutral (8, 30.8%);  
partially agree (1, 3.8%); agree (7, 26.9%); and strongly agree (9, 34.6%). 
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A procedure for updating the protocol is provided:  
 
Figure 1. Participant responses to Domain 3, question 8 related to updating procedures for the 
protocol. Adapted from REDCap.  
 
 
Domain four assesses the clarity of presentation regarding the PPH protocol; the first assessment 
of this domain included, “The recommendations are specific and unambiguous.”  One participant 
was neutral and the rest of participants agreed or strongly agreed with this assessment. The 
second assessment of this domain, “The different options for management of the condition or 
health issue are clearly presented.”  Participant responses included: partially disagree (1, 3.8%); 
partially agree (1, 3.8%); agree (8, 30.8%); and strongly agree (16, 61.5%).  The final assessment 
of this domain included, “Key recommendations are easily identifiable.” The responses to this 
question ranged from 3 to 7 with responses including: partially disagree (1, 3.8%); partially agree 
(1, 3.8%); agree (6, 23.1%); and strongly agree (18, 69.2%). 
 The fifth domain assesses applicability of the PPH protocol.  One assessment of this 
domain assesses, “The protocol provides advice and/or tools on how the recommendations can 
be put into practice.”  Participant responses included responses 5 to 7, with all participants 
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agreeing on varying levels. The sixth domain looks at editorial independence with one 
assessment assessing, “The views of the funding body have not influenced the content of the 
guideline.”  Participant responses ranged from neutral (4) to strongly agree (7): neutral (4, 
15.4%); partially agree (1, 3.8%); agree (9, 34.6%); and strongly agree (12, 46.2%). 
 The final domain assessed the quality of the protocol and recommendation of the protocol 
for use.  The overall quality of of the protocol was assessed by participants on a scale of 1 
(lowest possible quality) to 7 (highest possible quality).  Participant responses ranged from 4 to 7 
with 88% of responses rating as either a “6” or “7”. The final assessment of this domain assessed 
the recommendation of the protocol for use. The bar graph below demonstrates participant 
responses.   All participants recommended this protocol be implemented for use, or use with 
edits (See Figure 2).  
I would recommend this guideline for use:  
 
Figure 2. Bar graph of participants’ responses about recommendations for use of the protocol. 
Adapted from REDCap.  
 
 
 At the end of the survey, there was a section that allowed for open-ended responses.  
These open-ended questions assessed participants’ opinions regarding: desired protocol changes; 
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items participants liked about the protocol; and hindrances to protocol implementation. A 
prominent theme regarding changes of the PPH protocol was questioning of the definition of 
PPH. Many thought that definition was inaccurate and represented a large amount of blood loss. 
Another comment was to address spelling and grammatical changes to the protocol. A different 
participant questioned administration of methergine every two to four hours. The final comment 
regarding change was defining active management within the protocol. 
 The second question aimed to identify what participants liked about the protocol. Several 
participants liked that the protocol was “straightforward”, “clear”, and systematic in its 
processes.  Another participant enjoyed the risk assessment of the protocol and the quantifiable 
blood loss. A different participant liked the mention of tranexamic acid (TXA), and its use 
during a PPH. 
 The final open-ended question assessed hindrances to implementation of the PPH 
protocol. A reoccurring comment was “staff members”, “nurses”, and “physicians” being 
resistant to change.  A few participants commented that they would like a more thorough 
understanding of the logistics on QBL and how it would be completed systematically.  
Discussion 
 
 After reviewing the results of the survey, there have been changes made to the protocol 
(See Appendix F).  One change that was not made was redefining PPH. The definition of PPH 
was defined by ACOG in 2017 and is considered the most up-to-date definition of PPH by a 
professional organization.  Despite ACOG (2017) defining PPH as, “Postpartum hemorrhage is a 
blood loss of 1000 mL following all birth no matter the route of delivery; or excess blood loss 
following birth with vital sign changes including, hypotension and tachycardia,” the organization 
still emphasizes identifying blood loss of 500 mL or greater during a vaginal birth as a 
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complication and to intervene earlier rather than later.  Another change that was not made was 
the dosing of methergine administration. The administration of methergine, 0.2 mg 
intramuscularly every 2 to 4 hours, was defined by the CMQCC (2015). This dosage is also 
recommended by other drug administration guidelines and is considered the most appropriate 
administration and use of the medication during a PPH. Many providers use methergine outside 
this recommendation, however, for this protocol the use of evidence based methergine usage will 
remain within the protocol. 
 Changes that were included in the protocol included some grammatical and spelling 
changes. Another change to the protocol was defining active management during a PPH, and 
defining it earlier in the protocol. There was also added information regarding systematic QBL, 
to account for blood loss in the under buttocks drape. A change that was not recommended by 
participants but changed by the principal investigator was “starting hemoglobin less than 11 g/dL 
with medium or high risk factors” on the risk assessment chart. 
Limitations 
 There were some limitations to this qualitative study. The first limitation can be idenitifed 
as sample size. The sample size (N=26) was small and surveys were distributed to only one locoal 
community hospital. A small sample size and use of one community hospital may limit the 
applicability of the results to other institutions and groups. This project was also qualitative in 
nature, which can create issues due to self-reported data, partiularly inregards to the open-ended 
questions at the end. This creates a less systematic process to summarize results. 
Implications for Future Practice 
 This qualitative study results indicated a desire for want and acceptance of future use for 
a PPH protocol within this institution, after updated and appropriate changes to the protocol 
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(Appendix F). Future study to assess the changes to the protocol and have it reviewed by past 
participants may be indicated. There is also potential for future creation and implementation of a 
PPH cart to include supplies needed during a PPH.  
 It would also be beneficial to create some resources for systematic QBL, in regards to 
peri pads and lap sponges weights prior to use during a delivery, this could aid in the efficiency 
of calculating QBL.  A systematic approach could increase accuracy with QBL; however, the 
goal with QBL is not being exact but to be more accurate than visualizing EBL.   
 A PPH education slideshow presentation (Appendix G) was developed and presented by 
the protocol creator to 20 registered nurses after the survey results were collected. This 
presentation was directly formatted from the evidence used to formulate the protocol and from 
the CMQCC website. This allowed questions to be answered and education provided to 40% of 
the registered nurses on the unit. There were no providers, CNM or physician, which attended 
the presentation, which could be an opportunity for future presentations for the remaining 
registered nurses and providers. 
Conclusion 
 
This qualitative study revealed that there is some hesitation and misconceptions 
regarding PPH defintions and management based on staff knowledge at this local community 
hospital; however, there is a 100% participant desire for PPH protocol implementation. Future 
education to staff and providers could be beneficial to increase a standardized knowledge 
amongst caregivers.  The development of systematic QBL and a PPH cart could increase overall 
outcomes based on the literature (CMQCC, 2015).  It is imperative that all instituations caring 
for mothers and newborns in the immediate postpartum period be up to date on PPH education 
and the use of PPH protocols.  With the incident of maternal PPH on the rise, the better prepared 
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staff and orginizations, the better the outcomes (CMQCC, 2015). This has the potnetnial to 
decrease the overall maternal mortiality and morbidity rates related to PPH across the nation.   
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Appendix B 
 
PPH DNP Literature Review Matrix 
 
Citation 
(author/year) 
Purpose Design Key Findings Other Important 
Notes/ 
Information 
Savirón-Cornudella, 
R., Esteban, L. M., 
Laborda-Gotor, R., 
Rodríguez-
Solanilla, B., De 
Mucio, B., Sanz, G., 
& ... Castán-Mateo, 
S. (2018). Maternal 
morbidity after 
implementation of a 
postpartum 
hemorrhage 
protocol including 
use of misoprostol. 
International 
Journal Of 
Gynecology & 
Obstetrics, 140(2), 
198-204. 
doi:10.1002/ijgo.12
361. 
 
(Savirón‐Cornudella 
& et. al., 2018) 
To compare 
maternal 
morbidity 
before and 
after 
implementat
ion of a 
postpartum 
hemorrhage 
(PPH) 
protocol 
Retrospectiv
e analysis 
Pre-implementation 
group tended to 
have lower 
hemoglobin levels 
than did those in the 
post-implementation 
group: 811 (8.6%) 
versus 1349 (5.3%) 
for levels less than 
90 g/L, and 272 
(2.9%) versus 497 
(2.0%) for levels 
less than 80 g/L 
(both P<0.001) 
Implementation of 
the PPH protocol 
decreased rates of 
postpartum anemia 
and postpartum 
hysterectomy owing 
to uterine atony. 
Mansfield, J. 
(2018). Improving 
practice and 
reducing significant 
postpartum 
haemorrhage 
through audit. 
British Journal Of 
Midwifery, 26(1), 
35-43. 
doi:10.12968/bjom.
2018.26.1.35. 
 
To 
determine 
whether 
midwives 
considered 
risk factors 
for  
PPH and 
provided 
informed 
choice 
when 
Cohort Incidence of PPH 
>1000mL had 
decreased 
Practice Changes: 
-Risk assessment 
should be careful and 
ongoing. 
-Anticipation of risk 
supports early 
recognition and 
treatment  
- The importance of 
intravenous (IV) 
access. 
- To improve skills in 
recognition of PPH 
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(Mansfield, 2018) planning 
third stage  
managemen
t, and 
whether 
there was 
any 
relationship 
between 
third  
stage 
managemen
t and PPH 
 
and 
administration of 
uterotonics within 10 
minutes to 
prevent significant 
PPH  
-Women with 
estimated blood loss 
>500mL need 
closer monitoring 
with full assessment 
and 15-minute 
observations to 
ensure prompt 
recognition and 
treatment  
-Risk factors should 
be advised to have 
active management of 
the third stage. 
●● Midwives were 
encouraged to be 
more proactive in 
their administration 
of oxytocin in 
response to excess 
bleeding, important 
for the prevention of 
significant 
PPH in women who 
have had 
physiological 
management (Davis, 
2012). 
Doyle, J. L., Kenny, 
T. H., Gothard, M. 
D., Seagraves, E., 
McCarroll, M., & 
Silber, A. (2018). A 
Standardized 
Oxytocin 
Administration 
Protocol After 
Delivery to Reduce 
the Treatment of 
Clinical 
outcomes 
were 
compared 
before and 
after 
introduction 
of a quality 
measure: a 
standardize
d oxytocin 
Retrospectiv
e cohort 
study 
Standardized, 
higher-dose 
postpartum oxytocin 
may be associated 
with less PPH 
treatment in this 
cohort. These 
findings support 
standardization and 
set the stage for a 
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Postpartum 
Hemorrhage. The 
Joint Commission 
Journal on Quality 
and Patient Safety. 
 
(Doyle, & et. al., 
2018) 
 
protocol for 
PPH 
prophylaxis 
randomized 
controlled trial 
Shields, L. E., 
Wiesner, S., Fulton, 
J., & Pelletreau, B. 
(2015). 
Comprehensive 
maternal 
hemorrhage 
protocols reduce the 
use of blood 
products and 
improve patient 
safety. American 
journal of obstetrics 
and gynecology, 
212(3), 272-280. 
 
(Shields, Wiesner, 
Fulton, & 
Pelletreau, 2015). 
 
Assess the 
effectivenes
s of 
instituting a 
comprehens
ive protocol 
for the 
treatment of 
maternal 
hemorrhage 
within a 
large health 
care system 
Cohort  A significant 
reduction in blood 
product use per 
1000 births and a 
non-significant 
reduction in the 
number of patients 
who required 
puerperal 
hysterectomy. 
Supports 
implementation of 
standardized methods 
for postpartum care 
and treatment of 
maternal hemorrhage 
and support that this 
approach will reduce 
maternal morbidity. 
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Appendix C 
 
Evaluation Tool: Postpartum Hemorrhage Protocol Review 
 
On a scale from 1 to 7 please rate each question and circle according to the chart below. 
Strongly 
Disagree 
Disagree Partially  
Disagree 
Neutral Partially 
Agree 
Agree Strongly  
Agree 
1 2 3 4 5 6 7 
 
Domain 1: Scope and Practice 
1. The overall objectives of the protocol are specifically described. 
1 2 3 4 5 6 7 
 
2. The health questions covered by the protocol are specifically described. 
1 2 3 4 5 6 7 
 
3. The population (patients, public, etc.) to whom the guideline is meant to apply is specifically described. 
1 2 3 4 5 6 7 
 
 
Domain 2: Stakeholder Involvement 
1. The protocol includes individuals from all relevant professional groups. 
1 2 3 4 5 6 7 
 
2. The views and preferences of the target population (patients, public, etc.) have been sought. 
1 2 3 4 5 6 7 
 
3. The target users of the protocol are clearly defined. 
1 2 3 4 5 6 7 
 
 
Domain 3: Rigor of Development 
1. Systematic methods were used to search for evidence. 
1 2 3 4 5 6 7 
 
2. The criteria for selecting the evidence are clearly described. 
1 2 3 4 5 6 7 
 
3. The strengths and limitations of the body of evidence are clearly described. 
1 2 3 4 5 6 7 
 
4. The methods for formulating the recommendations are clearly described. 
1 2 3 4 5 6 7 
 
5. The health benefits, side effects, and risks have been considered in formulating the recommendations. 
1 2 3 4 5 6 7 
 
6. There is an explicit link between the recommendations and the supporting evidence. 
1 2 3 4 5 6 7 
 
7. The guideline has been externally reviewed by experts prior to its publication. 
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1 2 3 4 5 6 7 
 
8. A procedure for updating the protocol is provided. 
1 2 3 4 5 6 7 
 
 
 
Domain 4: Clarity of Presentation 
1. The recommendations are specific and unambiguous. 
1 2 3 4 5 6 7 
 
2. The different options for management of the condition or health issue are clearly presented. 
1 2 3 4 5 6 7 
 
3. Key recommendations are easily identifiable. 
1 2 3 4 5 6 7 
 
 
Domain 5: Applicability  
1. The protocol describes facilitators and barriers to its application 
1 2 3 4 5 6 7 
 
2. The protocol provides advice and/or tools on how the recommendations can be put into practice. 
1 2 3 4 5 6 7 
 
3. The potential resource implications of applying the recommendations have been considered. 
1 2 3 4 5 6 7 
 
4. The protocol presents monitoring and/or auditing criteria. 
1 2 3 4 5 6 7 
 
 
Domain 6: Editorial Independence 
1. The views of the funding body have not influenced the content of the guideline. 
1 2 3 4 5 6 7 
 
2. Competing interests of the guideline members have been recorded and addressed. 
1 2 3 4 5 6 7 
 
Domain 7: 
1. Rate the overall quality of this guideline. Scale of 1 (lowest possible quality) to 7 (highest possible quality). 
1 2 3 4 5 6 7 
 
2.  I would recommend this guideline for use: 
 
Yes Yes, with edits No 
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Recommendations: 
• What changes would you like to see in this protocol? 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
• What did you like about the protocol? 
 
 
 
 
 
 
 
 
 
 
 
 
• What hindrances do you see with implementation of the protocol? 
 
 
 
 
 
 
 
 
 
 
 
 
Comments: 
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Appendix E 
 
Labor Delivery Recovery Postpartum Unit 
Postpartum Hemorrhage Protocol 
 
I. Labor Delivery Recovery Postpartum 
 
II. Postpartum Hemorrhage (PPH): is a blood loss of 1000 mL following all birth no 
matter the route of delivery; or excess blood loss following birth with vital sign 
changes including, hypotension and tachycardia.  
 
III. PPH Risk Assessment: pertains to all patients upon admission and during labor 
progression. 
 
IV. PPH Staging: pertains to all postpartum patients who have lost 500 mL of blood or 
greater after birth; OR patients who are experiencing a 15% change in vital signs.  
 
V. Protocol Documents:  
 
i. Postpartum Hemorrhage Risk Assessment Tools 
ii. Postpartum Hemorrhage Staging Protocol 
iii. Postpartum Hemorrhage Medication Summary  
  
VI. Protocol: 
 
a.  At time of admission all patients will be assessed utilizing the PPH admission 
risk assessment tool (Appendix A). 
i. Document level to patient chart 
ii. Reevaluate risk during LDRP and modify risk assessment level as 
appropriate.  
b. 18 gauge IV access established on all patients at time of admission. 
c. Collect CBC and type and screen on all patients.  
d. Cross-match 2 units of blood and put on hold for all high-risk hemorrhage 
patients.  
e. Notify provider of patients who are high risk for PPH upon admission and notify 
of any risk assessment changes throughout labor.  
f. Notify provider and anesthesia of all patients who decline blood products, obtain 
declination form of blood products from patient. 
g. At time of delivery, all blood loss will be quantifiably measured. 
i. Utilizing graduated containers and blood soaked products on PPH cart 
scale.  
ii. Refer to PPH cart materials for pre-weights on various items: large blue 
peri pad, lap sponges and feminine pad.  
iii. Utilize weight conversion 1 gm=1 mL of blood loss 
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h. Following delivery, continue measuring blood loss until patient is stable and out 
of the postpartum recovery, 4 hours post vaginal delivery and 8 hours post 
cesarean delivery.  
i. Continue to monitor patient vitals signs including: heart rate, oxygen saturation, 
blood pressure and respirations every 5-15 minutes immediately postpartum until 
stable and then change vital sign assessment to normal postpartum standard. 
j. Active management of the third stage for all patients, including administration of 
postpartum oxytocin: Administer 10-40 units per 1000 mL solution at bolus of 
500mL/hr, titrate down per uterine tone; OR 10 units IM following delivery of the 
placenta. 
k. Document stage of OB hemorrhage (Appendix B) in delivery record.  
l. Notify provider if patient OB hemorrhage status has changed at any time during 
LDRP stay.  
  
36 
 
 
I. Labor and Delivery Admission Antepartum Hemorrhage Risk Level 
Low Risk Medium Risk High Risk 
• No previous uterine 
incisions or surgeries 
• Singleton pregnancy  
• <4 previous vaginal 
deliveries 
• No known bleeding 
disorders 
• No previous history 
of PPH 
• Maternal BMI < 30 
• Prior cesarean birth or 
uterine 
incision/surgery 
• Multiple gestation 
• >4 previous vaginal 
deliveries 
• Uterine fibroids  
• Polyhydraminos 
• History of previous 
PPH 
• Estimated fetal weight 
of 4000 gm or greater  
• Maternal BMI > 30 
• Placenta previa or low 
lying placenta 
• Placenta Accreta 
• Placenta Increta 
• Placenta Precreta 
• Placental abruption 
• Platelets less than 100 
mico/L 
• Active bleeding on 
admission 
• Anticoagulant therapy 
• Known bleeding 
disorder 
 
Labor and Delivery Reassessment Postpartum Hemorrhage Risk Level 
Low Risk Medium Risk High Risk 
• No previous uterine 
incisions or surgeries 
• Singleton pregnancy  
• <5 total previous 
vaginal deliveries 
• No known bleeding 
disorders 
• No previous history of 
PPH 
• Maternal BMI < 30 
• Uncomplicated 
vaginal delivery 
• No vaginal or genital 
tract trauma 
• Prior cesarean birth or 
uterine 
incision/surgery 
• Multiple gestation 
• >4 previous vaginal 
deliveries 
• Uterine fibroids or 
uterine anomaly 
• Polyhydraminos 
• History of previous 
PPH 
• Estimated fetal weight 
of 4000 gm or greater  
• Maternal BMI > 30 
• 5 or greater total 
vaginal births 
• Chorioaminonitis 
• Prolonged active labor 
>12 hours 
• Prolonged oxytocin 
use 
• Rapid Labor 
• Shoulder Dystocia 
• Magnesium Sulfate 
use 
• Placenta previa or low 
lying placenta 
• Placenta Accreta 
• Placenta Increta 
• Placenta Percreta 
• Placental abruption 
• Platelets less than 100 
mico/L 
• Anticoagulant therapy 
• Known bleeding 
disorders. 
• Hematocrit less than 
30% with other 
medium or high risk 
factors. 
• Starting hemoglobin 
less than 11 g/dL. 
• Active bleeding. 
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• Vaginal or genital 
tract trauma 
• Episiotomy 
• Vacuum or forceps 
use 
 
I. Patients, who have 2 or more medium risk factors, are considered high-risk level.  
II. Reassess all patients following delivery; they may have a change in risk status. 
III. Cross and match 2 units of packed red blood cells, to hold, for all patients who are 
high-risk status at any time during LDRP stay. 
 
II. Postpartum Hemorrhage Staging 
Stage 0: All Births  
• Monitor blood loss, and measure all 
blood using a quantifiable method, 
using graduated cylinders and PPH 
cart scale.  
• Use conversion 1 gm=1 mL of blood. 
• Administer oxytocin 40 units IV per 
1000 mL solution at 500 mL/hr and 
titrate down until uterine tone is 
stable; OR administer 10 units 
oxytocin IM. 
• Continuously monitor vital signs 
including: heart rate, blood pressure 
and respirations. 
• Monitor lochia and postpartum 
bleeding per postpartum recovery 
standard until patient is stable. 
• If blood loss is 500 mL or > post 
vaginal delivery or 1000 mL or > post 
cesarean delivery, continue below to 
Stage 1. 
• If there is a 15% change in vital signs 
continue to Stage 1. 
• If there is increased bleeding during 
postpartum or recovery period 
continue to Stage 1. 
Stage 1: OB Hemorrhage  
• Notify primary provider if not already 
present. 
• Maintain IV access. 
• Continue to administer oxytocin 40 
units IV per 1000 mL solution at 500 
mL/hr and titrate down until uterine 
tone is stable; OR administer 10 units 
oxytocin IM. 
• Apply fundal massage 
• Administer 0.2 mg of methergine IM, 
if not hypertensive, preeclamptic or 
eclamptic.  Can administer every 2-4 
hours up to maximum of 5 doses. 
• Proceed to Stage 2, if bleeding 
continues despite interventions of 
Stage 1. 
• Proceed to Stage 2, if bleeding is 
<1500 mL. 
• Proceed to Stage 2, if continued vital 
sign instability.  
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• If methergine not effective, move to 
next uterotonic agent. 
• Continue monitoring vitals signs and 
LOC.  
• Administer oxygen. 
• Continue to weight and record blood 
loss every 5-15 minutes. 
• Type and cross match for 2 units of 
packed RBCs STAT. 
• Empty bladder using Foley or straight 
catheter. 
Stage 2: OB Hemorrhage  
• Notify anesthesia, blood bank and 
emergency response team of 
hemorrhage. 
• Administer next uterotonic per 
provider orders: 
o Hemabate 250 mg IM, can 
administer every 20 minutes up 
to 3 times maximum. 
o Misoprostol 800 mcg 
sublingual or per rectum. 
• Start second 18 gauge IV. 
• Call blood bank to order blood 
products. 
• Administer blood products once 
received, using appropriate techniques 
including but not limited to: 2 patient 
identifiers, normal saline main line, 2 
RN witnesses to verify blood products 
and assess for blood product reactions.  
• Draw labs per provider orders. 
• Continue weighing blood loss and 
monitoring vital signs. 
• Move patient to OR. 
• Order TCA from pharmacy and 
administer per provider orders. 
• Proceed to Stage 3, if blood loss is 
greater than 1500 mL. 
• Proceed to Stage 3, if > 2 units of 
PRBCs administered. 
• Proceed to Stage 3, if vital signs 
remain unstable despite interventions. 
• Proceed to Stage 3, if suspected DIC. 
Stage 3: OB Hemorrhage  
• Order Massive Transfusion protocol 
per provider. 
• Transfer patient to OR, if not already. 
• Draw labs every 30-60 min, including 
CBC, Coagulation Panel II and Chem 
12 panel STAT. 
• Once stabilized move to intensive care 
unit for recovery. 
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• Continue monitoring vital signs, 
measuring EBL, and warming patient.  
• Circulate in OR. 
• Notify other personnel including: OR 
staff, anesthesia, blood bank, second 
OB provider, unit team leader, ICU 
and emergency response team, if not 
already done so.  
• Surgery preparation and surgery per 
provider.  
 
 
 
 
 
 
III. Postpartum Hemorrhage Medication Chart 
Pitocin (Oxytocin): 10-40 units, IV or IM Give to all postpartum patients during active 
management and until stable. 
Methergine (Methylergonivine): 0.2 mg IM 
every 2-4 4 hours. If first dose is ineffective, 
than other doses may not be effective either. 
Do not give to patients with preeclampsia, 
eclampsia or hypertension 
Hemabate (Carboprost tromthamine): 
250 mcg can administer IM every 20 minutes. 
Do not exceed 8 doses. 
Do not give to asthmatics. Can cause GI 
upset. 
Cytotec (Misoprostol): 600 to 800 mcg PO 
or sublingual x 1 dose. Can also be given 
rectally. 
Do not give if allergy to prostaglandins. 
Tranexmic Acid (TXA): 1 gram in 10 mL 
(100 mg/mL) IV at 1 mL per minute 
administered over 10 minutes. It should be 
given to women with PPH but not greater than 
3 hours postpartum. A second dose (1 gram) 
can be given 30 minutes after first dose, if 
needed. 
Do not give to patients with known bleeding 
or clotting disorders. 
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Appendix F 
 
Labor Delivery Recovery Postpartum Unit 
Postpartum Hemorrhage Protocol—Revised  
 
Labor Delivery Recovery Postpartum 
 
I. Postpartum Hemorrhage (PPH): is a blood loss of 1000 mL following all birth no 
matter the route of delivery; or excess blood loss following birth with vital sign 
changes including, hypotension and tachycardia.  
 
II. PPH Risk Assessment: pertains to all patients upon admission and during labor 
progression. 
 
III. PPH Staging: pertains to all postpartum patients who have lost 500 mL of blood or 
greater after birth; OR patients who are experiencing a 15% change in vital signs.  
 
IV. Active Management: use during third labor stage for all patients, including 
administration of postpartum oxytocin: administer 10-40 units per 1000 mL solution 
at bolus of 500mL/hr, titrate down per uterine tone; OR 10 units IM following 
delivery of the placenta. 
 
V. Protocol Documents:  
 
i. Postpartum Hemorrhage Risk Assessment Tools 
ii. Postpartum Hemorrhage Staging Protocol 
iii. Postpartum Hemorrhage Medication Summary  
  
VI. Protocol: 
 
a.  At time of admission all patients will be assessed utilizing the PPH admission 
risk assessment tool (Appendix A). 
i. Document level to patient chart 
ii. Reevaluate risk during LDRP and modify risk assessment level as 
appropriate.  
b. 18 gauge IV access established on all patients at time of admission. 
c. Collect CBC and type and screen on all patients.  
d. Cross-match 2 units of blood and put on hold for all high-risk hemorrhage 
patients.  
e. Notify provider of patients who are high risk for PPH upon admission and notify 
of any risk assessment changes throughout labor and postpartum.  
f. Notify provider and anesthesia of all patients who decline blood products, obtain 
declination form of blood products from patient. 
g. At time of delivery, all blood loss will be quantifiably measured. 
i. Utilizing graduated containers, under buttocks drapes and blood soaked 
products on PPH cart scale.  
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ii. Refer to PPH cart materials for pre-weights on various items: large blue 
peri pad, lap sponges and feminine pad.  
iii. Utilize weight conversion 1 gm=1 mL of blood loss 
h. Following delivery, continue measuring blood loss until patient is stable and out 
of the postpartum recovery, 4 hours post vaginal delivery and 8 hours post 
cesarean delivery.  
i. Continue to monitor patient vitals signs including: heart rate, oxygen saturation, 
blood pressure and respirations every 5-15 minutes immediately postpartum until 
stable and then change vital sign assessment to normal postpartum standard. 
j. Active management of the third stage for all patients, including administration of 
postpartum oxytocin: Administer 10-40 units per 1000 mL solution at bolus of 
500mL/hr, titrate down per uterine tone; OR 10 units IM following delivery of the 
placenta. 
k. Document stage of OB hemorrhage (Appendix B) in delivery record.  
l. Notify provider if patient OB hemorrhage status has changed at any time during 
LDRP stay.  
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I. Labor and Delivery Admission Antepartum Hemorrhage Risk Level 
Low Risk Medium Risk High Risk 
• No previous uterine 
incisions or surgeries 
• Singleton pregnancy  
• <4 previous vaginal 
deliveries 
• No known bleeding 
disorders 
• No previous history 
of PPH 
• Maternal BMI < 30 
• Prior cesarean birth or 
uterine 
incision/surgery 
• Multiple gestation 
• 4 or greater previous 
vaginal deliveries 
• Uterine fibroids  
• Polyhydraminos 
• History of previous 
PPH 
• Estimated fetal weight 
of 4000 gm or greater  
• Maternal BMI > 30 
• Placenta previa or low 
lying placenta 
• Placenta Accreta 
• Placenta Increta 
• Placenta Percreta 
• Placental abruption 
• Platelets less than 100 
mico/L 
• Active bleeding on 
admission 
• Anticoagulant therapy 
• Known bleeding 
disorder 
 
Labor and Delivery Reassessment Postpartum Hemorrhage Risk Level 
Low Risk Medium Risk High Risk 
• No previous uterine 
incisions or surgeries 
• Singleton pregnancy  
• <4 total previous 
vaginal deliveries 
• No known bleeding 
disorders 
• No previous history of 
PPH 
• Maternal BMI < 30 
• Uncomplicated 
vaginal delivery 
• No vaginal or genital 
tract trauma 
• Prior cesarean birth or 
uterine 
incision/surgery 
• Multiple gestation 
• 4 or greater previous 
vaginal deliveries 
• Uterine fibroids or 
uterine anomaly 
• Polyhydraminos 
• History of previous 
PPH 
• Estimated fetal weight 
of 4000 gm or greater  
• Maternal BMI > 30 
• 5 or greater total 
vaginal births 
• Chorioaminonitis 
• Prolonged active labor 
>12 hours 
• Prolonged oxytocin 
use 
• Rapid Labor 
• Shoulder Dystocia 
• Magnesium Sulfate 
use 
• Placenta previa or low 
lying placenta 
• Placenta Accreta 
• Placenta Increta 
• Placenta Percreta 
• Placental abruption 
• Platelets less than 100 
mico/L 
• Anticoagulant therapy 
• Known bleeding 
disorders. 
• Hematocrit less than 
30% with other 
medium or high risk 
factors. 
• Starting hemoglobin 
less than 11 g/dL with 
medium or high risk 
factors. 
• Active bleeding on 
admission. 
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• Vaginal or genital 
tract trauma 
• Episiotomy 
• Vacuum or forceps 
use 
 
IV. Patients, who have 2 or more medium risk factors, are considered high-risk level.  
V. Reassess all patients following delivery; they may have a change in risk status. 
VI. Cross and match 2 units of packed red blood cells, to hold, for all patients who are 
high-risk status at any time during LDRP stay. 
 
II. Postpartum Hemorrhage Staging 
Stage 0: All Births  
• Monitor blood loss, and measure all 
blood using a quantifiable method, 
using graduated cylinders and PPH 
cart scale.  
• Use conversion 1 gm=1 mL of blood. 
• Administer oxytocin 40 units IV per 
1000 mL solution at 500 mL/hr and 
titrate down until uterine tone is 
stable; OR administer 10 units 
oxytocin IM. 
• Continuously monitor vital signs 
including: heart rate, blood pressure 
and respirations. 
• Monitor lochia and postpartum 
bleeding per postpartum recovery 
standard until patient is stable. 
• If blood loss is 500 mL or > post 
vaginal delivery or 1000 mL or > post 
cesarean delivery, continue below to 
Stage 1. 
• If there is a 15% change in vital signs 
continue to Stage 1. 
• If there is increased bleeding during 
postpartum or recovery period 
continue to Stage 1. 
Stage 1: OB Hemorrhage  
• Notify primary provider if not already 
present. 
• Maintain IV access. 
• Continue to administer oxytocin 40 
units IV per 1000 mL solution at 500 
mL/hr and titrate down until uterine 
tone is stable; OR administer 10 units 
oxytocin IM. 
• Apply fundal massage 
• Administer 0.2 mg of methergine IM, 
if not hypertensive, preeclamptic or 
eclamptic.  Can administer every 2-4 
hours up to maximum of 5 doses. 
• Proceed to Stage 2, if bleeding 
continues despite interventions of 
Stage 1. 
• Proceed to Stage 2, if bleeding is 
<1500 mL. 
• Proceed to Stage 2, if continued vital 
sign instability.  
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• If methergine not effective, move to 
next uterotonic agent. 
• Continue monitoring vitals signs and 
LOC.  
• Administer oxygen. 
• Continue to weight and record blood 
loss every 5-15 minutes. 
• Type and cross match for 2 units of 
packed RBCs STAT. 
• Empty bladder using Foley or straight 
catheter. 
Stage 2: OB Hemorrhage  
• Notify anesthesia, blood bank and 
emergency response team of 
hemorrhage. 
• Administer next uterotonic per 
provider orders: 
o Hemabate 250 mg IM, can 
administer every 20 minutes up 
to 3 times maximum. 
o Misoprostol 800 mcg 
sublingual or per rectum. 
• Start second 18 gauge IV. 
• Call blood bank to order blood 
products. 
• Administer blood products once 
received, using appropriate techniques 
including but not limited to: 2 patient 
identifiers, normal saline main line, 2 
RN witnesses to verify blood products 
and assess for blood product reactions.  
• Draw labs per provider orders. 
• Continue weighing blood loss and 
monitoring vital signs. 
• Move patient to OR. 
• Order TXA from pharmacy and 
administer per provider orders, can 
administer a second dose 30 min later 
if ordered by provider. 
• Proceed to Stage 3, if blood loss is 
greater than 1500 mL. 
• Proceed to Stage 3, if > 2 units of 
PRBCs administered. 
• Proceed to Stage 3, if vital signs 
remain unstable despite interventions. 
• Proceed to Stage 3, if suspected DIC. 
Stage 3: OB Hemorrhage  
• Order Massive Transfusion protocol 
per provider. 
• Transfer patient to OR, if not already. 
• Once stabilized move to intensive care 
unit for recovery. 
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• Draw labs every 30-60 min, including 
CBC, Coagulation Panel II and Chem 
12 panel STAT. 
• Continue monitoring vital signs, 
measuring EBL, and warming patient.  
• Circulate in OR. 
• Notify other personnel including: OR 
staff, anesthesia, blood bank, second 
OB provider, unit team leader, ICU 
and emergency response team, if not 
already done so.  
• Surgery preparation and surgery per 
provider.  
 
 
 
 
 
 
III. Postpartum Hemorrhage Medication Chart 
Pitocin (Oxytocin): 10-40 units, IV or IM Give to all postpartum patients during active 
management and until stable. 
Methergine (Methylergonivine): 0.2 mg IM 
every 2-4 4 hours. If first dose is ineffective, 
than other doses may not be effective either. 
Do not give to patients with preeclampsia, 
eclampsia or hypertension 
Hemabate (Carboprost tromthamine): 
250 mcg can administer IM every 20 minutes. 
Do not exceed 8 doses. 
Do not give to asthmatics. Can cause GI 
upset. 
Cytotec (Misoprostol): 600 to 800 mcg PO 
or sublingual x 1 dose. Can also be given 
rectally. 
Do not give if allergy to prostaglandins. 
Tranexmic Acid (TXA): 1 gram in 10 mL 
(100 mg/mL) IV at 1 mL per minute 
administered over 10 minutes. It should be 
given to women with PPH but not greater than 
3 hours postpartum. A second dose (1 gram) 
can be given 30 minutes after first dose, if 
needed. 
Do not give to patients with known bleeding 
or clotting disorders. 
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Appendix G 
 
Postpartum Hemorrhage PowerPoint Outline 
 
I. Postpartum Hemorrhage 
 
II.  Why PPH Education? 
a. Incidence of obstetric hemorrhage is increasing. 
b. PPH impacts up to 5% of all births, 125,000 women a year who are affected by 
PPH 
c. Hemorrhage deaths reviewed generally have high “preventability” assessment. 
d. United States ranks 47th in the world for maternal mortality.  
 
III. The goal of this presentation: 
a.  is to affirm and broaden current knowledge of PPH. 
b. Increase understanding of interventions/medications used during PPH.  
 
IV. Maternal Morbidity v. Mortality 
a. Maternal morbidity is defined as negative effects due to pregnancy or childbirth. 
b. Maternal mortality is maternal death due to pregnancy or childbirth. 
 
V. Maternal Facts 
a. Blood volume 
i. women about 6 L by 30 weeks 
b. Uterus weight 
i. Pre pregnancy: 40 – 70 grams 
ii. Third trimester: 1,200 grams 
c. Uterine cavity capacity 
i. Pre pregnancy: 10 mL 
ii. Third trimester: 5,000 mL 
d. Blood Flow 
i. Pre pregnancy: 2% cardiac output 
ii. Third trimester: 17% cardiac output: 600 – 800 mL/min 
 
VI. Defining Postpartum Hemorrhage 
a. WHO defines 
i. EBL of > 500 mL an “alert line”  
ii. > 1000 mL an “action line” 
b. ACOG  
i. Cumulative EBL > 1,000 mL for either vaginal or cesarean birth with 
enhanced surveillance and early interventions, as needed, for 500-1000 
mL 
c. Average:  
i. 500 mL for NSVD  
ii. 750-1000 mL for C/S  
iii. For most women these average amounts of blood loss are well tolerated 
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d. 4-5% of women > 1000 mL - A clinically significant amount!! 
 
VII. Primary PPH 
a. Primary PPH is defined as a cumulative blood loss of 1000 mL or more within the 
first 24 hours of delivery regardless of route of delivery.  
b.  It is also defined as significant blood loss with symptoms of hypovolemia, 
including tachycardia and hypotension, which occurs within the first 24 hours of 
delivery.  
c. All women with a total blood loss of 500 to 1000 mL postpartum should be 
monitored closely and may require PPH intervention to prevent further morbidity 
or mortality. 
 
VIII. Secondary PPH 
a. Secondary PPH is defined as excessive vaginal or uterine bleeding that occurs 
between 24 hours post-delivery up to 12 weeks postpartum. 
b.  The risk of secondary PPH peaks during the first two weeks postpartum.  
 
IX. The 4 T’s 
a. Tone: overall muscle tone of uterus. Typically felt in fundus but can also be a 
result exclusively of lower uterine segment. 
i. Uterine tone is responsible for approximately 70 to 80% of all PPH 
incidence. The other three etiologies are responsible for the remaining 20-
30% of PPH incidence.  
b.  Tissue: involves any foreign tissue retained after delivery, which may include 
retained membranes, retained placentas in their entirety, and retained placental 
fragments  
c. Trauma: any laceration caused by birth, such as lacerations to perineal tissue or 
cervix, hematomas, and uterine rupture.  
d.  Thrombin: refers to identifying any bleeding disorders that may lead to PPH 
including incidents of HELLP and DIC. 
 
X. Quantifiable blood loss: 
a. Is systematic blood loss estimation using a scale and reference materials. 
b. It is NOT an exact science.  
c. Literature shows we underestimate blood loss by not using QBL.  
d. Underestimation leads to delay of PPH treatment 
e. It is recommended that QBL be done every time and at every birth and through 
postpartum recovery, NOT just during a PPH. 
i. Why?  
ii. Because all blood loss adds up. 
iii. Not all women have the same hgb reserve or physiological response to 
blood loss.  
iv. Normal for one is not normal for another. 
v. It is also important to acknowledge the steady trickles not just the large 
gushes because it all adds up. 
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vi. If its not routine standard, we don’t know how to do it when we need it.  
And we don’t recognize WHEN we need it until late in the game… 
vii. Goal is NOT a “perfect, precise” number 
viii. Of course inaccuracies will persist 
1. Amniotic fluid contamination, urine 
2. Blood clots/other mixed with fluid in the drapes 
3. Look an canister during c-section prior to irrigation and account 
for used lap sponges. 
ix. QBL increases our knowledge of blood loss and is more accurate than 
EBL 
f. When patient has a hemorrhage, doing QBL is second nature for the 
team/staff/unit 
g. “This is how we do it here….” 
h. Allows for earlier recognition of excessive blood loss and improved 
communication among team members. 
i. Avoid delay in management of excessive blood loss 
 
XI. Identifying Risk Factors 
a. Early identification of PPH is to identify women at greater risk for PPH on 
admission, before delivery has happened. 
b. PPH risk should be reassessed throughout labor to account for labor risk factors.  
c. 1/3 of women have no PPH risk factors.  
d. PPH admission tools are shown to identify 60-85% of patients who will have a 
PPH 
e. PPH can occur in low-risk women, but is more likely to occur in women with 
higher risks of PPH  
f. All women should be screened on admission for risk of PPH.  
g. Women should later be rescreened and regularly during labor PPH risk 
assessment changes. 
h. Patients, who have 2 or more medium risk factors, are considered high-risk level.  
i. Reassess all patients following delivery; they may have a change in risk status. 
j. Cross and match 2 units of packed red blood cells, to hold, for all patients who are 
high-risk status at any time during LDRP stay. 
 
XII. PPH Medications 
a. 1st Line PPH Medication: Pitocin (oxytocin) 
i. Used for BOTH prophylactic and treatment of PPH. 
ii. Has fewest side effects of all PPH medications. 
iii. Contraindication: allergy/intolerance to drug. 
iv. Dosage: 10-40 units/500-1000 mL IV Fluid with initial rate of 500 mL/hr 
or > then titrated down. 
v. Onset: rapid onset when infused intravenously; titrate according to uterine 
tone and bleeding  
vi.  IM: 3-5 minutes, with a clinical response lasting about 2-3 hours 
vii. Side Effects: n/v; rapid infusion can cause hypotension and tachycardia; 
prolonged use can lead to hyponatremia leading to water intoxication. 
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viii.  Storage: Room temperature 
b. 2nd Line PPH Medications 
i. Used for ONLY treatment 
ii. 3 options for 2nd Line Treatment: 
iii. Methergine 
iv. Hemabate 
v. Cytotec 
c. WHO states, “Decisions in such situations must be guided by the experience of 
the provider, the availability of the drugs, and by known contraindications.” 
d. Some recommendations state that methergine should be considered the best 
option for 2nd line choices; however, there is little data to evaluate which second 
line therapy is preferable. 
e. It is recommended that all units pick a standard “first choice, 2nd line uterotonic 
of choice”.  
 
XIII. Methergine (methylergonovine maleate): 
a. Use: is FDA-approved for routine management of the third stage of labor and 
postpartum uterine atony. 
b. Dose: single dose of 0.2 mg IM or 0.2 mg PO single tab 
c. Onset:  
d. PO onset of action is 5-10 minutes 
e. IM onset of action is 2-5 minutes 
f. Contraindicated: in preeclampsia or hypertensive patients, including patients 
who have recently received ephedrine.  
g. Side Effects: n/v and exaggerated blood pressure responses.  
h. Toxicity Sxs: chest pain, arterial spasm, myocardial infarction, and 
hallucinations. 
i. Storage: IM medication must be refrigerated. 
 
XIV.  Hemabate (carboprost or 15 methyl PGF2 alpha): 
a. Use: is FDA-approved for treatment of PPH secondary to uterine atony not 
responsive to conventional treatment (massage and oxytocin). 
b. Dose: 250 mcg IM 
c. Peak Plasma Level: 30 min after injection 
d. Administration: A 250 mcg dose can be given every 15 minutes 
e. Max Dose: Do not exceed 2 mg or 8 doses TOTAL 
f. Success Rate: 75% success after 1 dose. 
g. Storage: Needs refrigerated. 
h. Contraindications: Asthma, liver disease, heart disease and hypersensitivity to 
drug. 
i. Side effects: n/v, diarrhea, fever (up to 1 degree C), bronchospasm. 
j. In general, chorioamnionitis can cause these uterotonics to be less effective, 
particularly hemabate. 
 
XV. Cytotec (misoprostol): 
a. Use:  
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b. is FDA approved for reducing the risk of NSAID-induced gastric ulcers not for 
uterine atony. 
c. is water-soluble and is quickly absorbed after sublingual, oral, vaginal, and rectal 
use. 
d. Sides Effects: fever (22-58% of patients), diarrhea, shivering, and headaches. 
e. Administration Facts:  
f. plasma concentration is higher than when given rectally and maintained for longer 
periods of time 
g. the time to peak plasma concentration is shortest for sublingual administration 
h. Due to ingestion processes, it is unlikely that misoprostol would be effective if 
hemabate has failed or vice versa 
 
XVI. Tranexamic acid (TXA) 
a. TXA is an inhibitor of fibrinolysis and may reduce bleeding in the setting of 
coagulation abnormalities.  
b. It is NOT an initial treatment of PPH. 
c. It has been used by France and United Kingdom for years. 
d. The WOMAN international randomized controlled trial showed a 31% reduction 
in death from hemorrhage when 1g of TXA was administered intravenously 
within 3 hours after the diagnosis of PPH. This trial included over 20,000 women 
with PPH. 
e. The WOMAN trial demonstrated that TXA is most effective when given within 3 
hours of hemorrhage diagnosis, hence the recommendation that it be considered 
relatively early in the hemorrhage protocol. 
f. Administer if bleeding continues after higher dose oxytocin and methergine have 
been administered and additional interventions (e.g. Hemabate or compression 
balloons) are being considered.  
g. TXA should be considered for inclusion in the unit OB Hemorrhage medication 
kit for rapid accessibility. 
h.  Restriction to a hemorrhage medication kit may reduce the risk of look-alike drug 
error (specifically do not put TXA in same place as local anesthetics).  
i. Fibrinogen replacement in the setting of fibrin breakdown is most effective if 
given AFTER administration of TXA (but don't delay blood products to 
administer TXA if the clinical condition calls for transfusion).  
j. TXA solution for intravenous use contains 100mg per ml. can be used as slow IV 
injection or diluted within a 50 or 100ml IV piggyback to be given as an 
intravenous infusion.  
k. To avoid hypotension, administer at a rate not to exceed 100 mg per minute. (i.e 
1gm over 10 minutes)  
l. Prepare the same day the solution is to be used; discard any remaining solution 
after single-use.  
m. May be mixed with most solutions for infusion such as electrolyte, carbohydrate, 
amino acid, and dextran solutions.  
n. Do not add heparin to injection or mix with blood; do not mix with solutions 
containing penicillin.  
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XVII. PPH Hemorrhage Carts/Kits 
a. Quick access to emergency supplies 
b. Refrigerator for meds 
c. Establish necessary items and par levels 
d. Label drawers/compartments 
e. Include checklists 
f. Develop process for checking and restocking 
g. Educate nursing and provider staff 
h. Can be simple or advanced as a code cart with refrigerator included.  
 
XVIII. Basic Needs For Carts/Kits 
a. IV start supplies 
b. IV fluids and tubing 
c. PPH medications 
d. Syringes 
e. Needles 
f. Alcohol 
g. Scale 
h. Graduated Cylinder 
i. Foley Catheter 
j. Bakri/Uterine Balloon 
k. Instruments: retractors, speculums, speculums, suture etc. 
l. Reference Guides for Weighing Items 
m. PPH Checklist 
 
XIX. Use of PPH Protocols and Checklists/Staging 
a. PPH protocols and checklists are highly recommended along with PPH kits and 
carts.  
b. The idea behind a checklist is to keep a team focused approach and have a 
sequence of what is next from all angles. 
c. See PPH protocol. 
 
XX. PPH Economics 
a. Blood products are VERY expensive 
b. Hemabate is ALSO VERY expensive 
c. Surgical Intervention is very expensive 
d. Math: more early interventions 
=fewer hemorrhages that reach “massive” 
=fewer high level (expensive) interventions 
 
XXI. Recommendations 
a. All relevant uterotonic medications should be readily available for emergent use. 
b. All LDRP units should have a standardized medication regimen. 
c. All LDRP units should use quantifiable blood loss. 
d. PPH trays, carts or kits should be kept on LDRP units and ready for emergent 
need/use. 
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e. All team members should be well versed on PPH: lab, blood bank, RN, OB 
providers, anesthesia, OB technicians etc. 
f. PPH management is a TEAM effort. 
g. Active management of the 3rd stage for all. 
h. Vigilant vital sign monitoring 
i. 1/3 of patients will have no risk factors prior to labor 
j. Must be prepared for every patient 
k. QBL every delivery so can respond early 
 
XXII. Preparation is key 
a. What resources are available? 
b. What resources need to be developed? 
c. Do all team members know what they are and how to deploy/utilize these 
resources? 
d. Early recognition of triggers: empowering any team member to activate protocol 
and call for help 
e. Call it what it is and don’t be afraid to say to the team we are having a PPH 
f. Sequential utilization of patient monitoring, evaluation, medications, and 
procedures. 
 
 
 
 
 
 
